| Literature DB >> 32187982 |
Ying-Wu Lin1,2,3.
Abstract
The widespread use of uranium for civilian purposes causes a worldwide concern of its threat to human health due to the long-lived radioactivity of uranium and the high toxicity of uranyl ion (UO22+). Although uranyl-protein/DNA interactions have been known for decades, fewer advances are made in understanding their structural-functional impacts. Instead of focusing only on the structural information, this article aims to review the recent advances in understanding the binding of uranyl to proteins in either potential, native, or artificial metal-binding sites, and the structural-functional impacts of uranyl-protein interactions, such as inducing conformational changes and disrupting protein-protein/DNA/ligand interactions. Photo-induced protein/DNA cleavages, as well as other impacts, are also highlighted. These advances shed light on the structure-function relationship of proteins, especially for metalloproteins, as impacted by uranyl-protein interactions. It is desired to seek approaches for biological remediation of uranyl ions, and ultimately make a full use of the double-edged sword of uranium.Entities:
Keywords: metal-binding site; metalloproteins; structure-function; toxicity; uranyl
Mesh:
Substances:
Year: 2020 PMID: 32187982 PMCID: PMC7175365 DOI: 10.3390/biom10030457
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Scheme 1A schematic view of uranyl binding to proteins and structural-functional impacts.
Figure 1(a) Biodistribution of uranyl ions in serum proteins. A model of uranyl binding to fetuin-A is shown as an inset. Reprinted with permission from Ref. [22], Copyright 2013 American Chemical Society. (b) An overall structure of HSA showing the four potential metal-binding sites. I-IIIA and I-IIIB indicate the protein sub-domains. (c) A theoretical model of uranyl-peptide complex based on DFT calculation. Reprinted with permission from Ref. [28], Copyright 2013, Wiley-VCH. (d) Strategies for design of cyclic peptides with high binding affinity of uranyl ion. Reprinted with permission from Ref. [31] with slight modification, Copyright 2014, Wiley-VCH.
Figure 2Modeling structures of UO22+ binding to protein surface. (a) A model of UO22+ binding to Cyt b5 at surface residues, Glu37 and Glu43 [44]; (b) A model of UO22+ binding to Cyt c at surface residues, Glu66 and Glu69 [45]; (c) A model of UO22+ binding to Zn4SmtA species. Reprinted with permission from Ref. [49], Copyright 2016 American Chemical Society; (d) A model of UO22+ binding to Ub at surface residues, Glu18 and Asp21 (cyan). The structure of free Ub (gray) was shown for comparison [53]. Close-up views of the uranyl binding sites were shown as insets, highlighting the coordination and H-bonding interactions.
Figure 3(a) An X-ray crystal structure (PDB code 1A8E) showing the coordination environment of Fe3+ in the N-lobe of Tf (left), and a proposed model of uranyl binding to the Fe3+ site (right) Reprinted with permission from Ref. [61], Copyright 2007 American Chemical Society. (b) An X-ray crystal structure (PDB code 1EXR) showing the binding of four Ca2+ ions in CaM (left), and a theoretical model of uranyl binding with electronic density based on DFT calculation (right). Reprinted with permission from Ref. [65], Copyright 2016 American Chemical Society.
Figure 4Rational design of an artificial uranyl binding site in native and de novo protein scaffolds. (a) Rational design of an artificial UO22+-binding site in NikR by V72S/H76′D/C95D mutations (left) [67], and display of the triple mutant on yeast surface (right) [68]; (b) An X-ray crystal structure of a de novo protein with an artificial UO22+-binding site, and a close-up view of uranyl-binding site, highlighting the coordination and H-bond interactions (PDB code 4FZP, chain B) [10].
Figure 5(a) An X-ray crystal structure of the N-lobe of holotransferrin (PDB code 1A8E) (left) and the proposed conformational changes upon uranyl binding to the Fe3+ site (right). Reprinted with permission from Ref. [61], Copyright 2007 American Chemical Society. (b) A schematic presentation of uranyl binding to Tf in several steps with different rates. Reprinted with permission from Ref. [79] with slight modification, Copyright 2011 American Chemical Society.
Figure 6Uranyl-induced disruption of protein-protein/DNA/ligand interactions. (a) A schematic presentation of the disruption of Cyt b5-Cyt c interactions by uranyl ions, adapted from [45]. (b) A schematic presentation of uranyl inhibition of DNA binding to proteins and control studies [84]. (c) A predicted model of uranyl binding to the Ca2+-binding site in C-reactive protein (CRP) (left), which inhibits the binding of Ca2+ ions and the ligand, phosphorylcholine, as shown in an X-ray crystal structure (PDB code 1B09) (right). Reprinted with permission from Ref. [87], Copyright 2010, The Protein Society.
Uranyl binding to some proteins or peptides and the structural-functional impacts.
| Protein/Peptide | Binding Site | Affinity ( | Structural and Functional Impacts | Refs. |
|---|---|---|---|---|
| Fetuin-A | 3 binding sites | ~30 nM–10 µM | The secondary structure was slightly modified upon binding of 3 eq. of UO22+ | [ |
| HSA | 4 potential binding sites | 1.7 µM | Conformational changes for the secondary structure | [ |
| Cyclic peptides | 1-2 binding sites | logK = 8.2~11.3 | Design of uranyl sensors | [ |
| Phosphorylated OPN | 9 binding sites | 3.6 nM | Structural rearrangements | [ |
| Cyt | 1 binding site | 10 µM | Slight conformational alterations of both the heme-binding domain and the hydrophobic core. | [ |
| Cyt | 1 binding site | 87 µM | Induces conformational changes and decreases the peroxidase activity | [ |
| Cyt | Not determined | 30 µM | Interference of the interactions between Cyt | [ |
| SmtA | 1 binding site | ~10-10 M | Very minor adjustments of either backbone or side chains | [ |
| Ub | 1-binding site | Not determined | Slight conformational changes and a different dynamic property | [ |
| Tf | 2 binding sites | 2.8 µM | Large conformational changes and interference of the protein-receptor interactions | [ |
| CaM | 4 binding sites | 32 nM (pH 6) | Conformational changes for the EF-hand binding motif | [ |
| Engineered CaM | 4 binding sites | 5 nM (pH 6) | Conformational changes for the EF-hand binding motif | [ |
| CRP | 1 binding site | 0.68 µM | Disrupts ligand binding to the protein | [ |
| Engineered | 1 binding site | 53 nM | High uranyl selectivity; | [ |
| 1 binding site | 7.4 fM | Conformational changes for the secondary structure | [ |